Longeveron LLC (LGVN) - Total Liabilities
Based on the latest financial reports, Longeveron LLC (LGVN) has total liabilities worth $5.18 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore LGVN net asset momentum to track the company's year-over-year net asset growth rate.
Longeveron LLC - Total Liabilities Trend (2018–2025)
This chart illustrates how Longeveron LLC's total liabilities have evolved over time, based on quarterly financial data. See Longeveron LLC free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Longeveron LLC Competitors by Total Liabilities
The table below lists competitors of Longeveron LLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JPEL Private Equity Ltd
LSE:JPEL
|
UK | $537.00K |
|
Duckshin Housing Co. Ltd
KQ:090410
|
Korea | ₩86.10 Billion |
|
Chonbang
KO:000950
|
Korea | ₩9.17 Billion |
|
Allied Industrial Ltd
TWO:4702
|
Taiwan | NT$218.53 Million |
|
Big Yellow Group PLC
LSE:BYG
|
UK | GBX519.91 Million |
|
Muar Ban Lee Group Bhd
KLSE:5152
|
Malaysia | RM103.00 Million |
|
Pelangio Exploration Inc
V:PX
|
Canada | CA$543.51K |
|
CKX Lands Inc
NYSE MKT:CKX
|
USA | $281.10K |
Liability Composition Analysis (2018–2025)
This chart breaks down Longeveron LLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see LGVN market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Longeveron LLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Longeveron LLC (2018–2025)
The table below shows the annual total liabilities of Longeveron LLC from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $4.59 Million | +24.93% |
| 2024-12-31 | $3.67 Million | -31.22% |
| 2023-12-31 | $5.34 Million | -22.76% |
| 2022-12-31 | $6.91 Million | +30.06% |
| 2021-12-31 | $5.31 Million | -27.05% |
| 2020-12-31 | $7.28 Million | +18.63% |
| 2019-12-31 | $6.14 Million | +65.60% |
| 2018-12-31 | $3.71 Million | -- |
About Longeveron LLC
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; com… Read more